Lineage Cell Therapeutics, Inc. Tax Withholding Paid on Stock Awards
Lineage Cell Therapeutics, Inc. (LCTX) reported Tax Withholding Paid on Stock Awards of $40.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $0.00.
- Lineage Cell Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $40.00K, a 166.67% increase year-over-year.
- Lineage Cell Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $1.00K.
- Lineage Cell Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $0.00.
- Lineage Cell Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $16.00K, a 30.43% decline from fiscal 2024.
- Lineage Cell Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $23.00K, a 37.84% decline from fiscal 2023.
- Lineage Cell Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $37.00K, a 117.65% increase from fiscal 2022.
- Lineage Cell Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $17.00K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $40.00K 10-Q · filed 2026-08-06 | $41.00K derived: sum of 3 quarters · filed 2026-08-06 | $41.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $40.00K 10-Q · filed 2026-05-12 | $41.00K derived: sum of 2 quarters · filed 2026-05-12 | $41.00K derived: sum of 3 quarters · filed 2026-05-12 | $41.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.00K derived: sum of 3 quarters · filed 2026-08-06 | $16.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $15.00K 10-Q · filed 2025-11-06 | $15.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $15.00K 10-Q · filed 2026-08-06 | $15.00K derived: sum of 3 quarters · filed 2026-08-06 | $15.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $15.00K 10-Q · filed 2026-05-12 | $15.00K derived: sum of 2 quarters · filed 2026-05-12 | $15.00K derived: sum of 3 quarters · filed 2026-05-12 | $15.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $23.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $23.00K 10-Q · filed 2025-11-06 | $23.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $23.00K 10-Q · filed 2025-08-12 | $23.00K derived: sum of 3 quarters · filed 2025-08-12 | $23.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $23.00K 10-Q · filed 2025-05-13 | $23.00K derived: sum of 2 quarters · filed 2025-05-13 | $23.00K derived: sum of 3 quarters · filed 2025-05-13 | $23.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $0.00 derived: sum of 2 quarters · filed 2025-03-10 | $0.00 derived: sum of 3 quarters · filed 2025-03-10 | $37.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $37.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $37.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $37.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $17.00K 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |